Visiongain Report: Global Rheumatoid Arthritis Drugs Market Estimated to Grow at a CAGR of 0.6% in the Second Half of the Forecast Period
- Global Rheumatoid Arthritis Drugs Market Forecast 2020-2030
- Biologics, Non-Biologics, NSAIDs, sDMARDs and Others
LONDON, March 18, 2020 /PRNewswire/ -- The global Rheumatoid Arthritis market is estimated to have reached $58bn in 2018 and is expected to grow at a CAGR of 0.6% in the second half of the forecast period. In 2018, the biologics submarket held 85% of the global Rheumatoid Arthritis market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 236-page report you will receive 180 tables and 121 figures– all unavailable elsewhere.
The 236-page Visiongain report provides clear detailed insight into the rheumatoid arthritis market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
To request sample pages from this report please contact Sara Peerun at email@example.com or refer to our website: https://www.visiongain.com/report/global-rheumatoid-arthritis-drugs-market-forecast-2020-2030/#download_sampe_div
• Global Rheumatoid Arthritis Market forecast from 2020-2030
• Revenue forecasts for the Rheumatoid Arthritis Market by Drug Class from 2020-2030:
• Non-Biologics: NSAIDs, sDMARDs, Others
• Revenue forecasts for the Rheumatoid Arthritis Market by Drugs from 2020-2030:
• Simponi/Simponi Aria
• Revenue forecasts for the Rheumatoid Arthritis Market by Region from 2020-2029:
• North America: U.S., Canada
• Europe: Germany, UK, France, Italy, Spain, Russia, Rest of Europe
• Asia-Pacific: Japan, China, India, Rest of Asia-Pacific
• Latin America: Brazil, Mexico, Rest of Latin America
• Middle East & Africa: Saudi Arabia, South Africa, Rest of MEA
• Profiles of these selected leading companies:
• Amgen, Inc.
• Bristol-Myers Squibb
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Johnson & Johnson
• Merck & Co.
• Novartis AG
• Sanofi S.A.
• Analysis of the Drivers, Restraints, Opportunities and Threats of the global rheumatoid arthritis drugs market
• The report also includes SWOT Analysis of the Global rheumatoid arthritis drugs market
• Key questions answered by this report:
• How is the Rheumatoid Arthritis drugs market evolving?
• What is driving and restraining the Rheumatoid Arthritis drugs market?
• What are the market shares of each segment of the overall Rheumatoid Arthritis drugs market in 2018?
• How will each Rheumatoid Arthritis drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030?
• How will the market shares for each Rheumatoid Arthritis drugs submarket develop from 2020 to 2030?
• Which individual therapies will prevail and how will these shifts be responded to?
• What will be the main driver for the overall market from 2020 to 2030?
• How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2030?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry evolve during the period between 2020 and 2030?
To request a report overview of this report please contact Sara Peerun at firstname.lastname@example.org or refer to our website: https://www.visiongain.com/report/global-rheumatoid-arthritis-drugs-market-forecast-2020-2030/
Did you know that we also offer a report add-on service? Email email@example.com to discuss any customized research needs you may have.
Companies covered in the report include:
Ablynx NV Sanofi
Adheron Therapeutics, Inc.
Akari Therapeutics Plc
Araim Pharmaceuticals, Inc.
Artax Biopharma, Inc.
Astellas Pharma Inc
Cambridge Biotechnology Ltd.
Celltex Therapeutics Corp.
Chugai Pharmaceutical Co., Ltd.
Coherus BioSciences Inc
Dr Reddy's Laboratories
Five Prime Therapeutics
Gilead Sciences, Inc.
Glenmark Pharmaceuticals Ltd.
Hanmi Pharmaceutical Co Ltd.
Innate Pharma - IPO Pending
Izana Bioscience Ltd.
Johnson & Johnson
Kyowa Hakko Kirin Co Ltd
Merck & Co.
Mitsubishi Tanabe Pharma
NeuBase Therapeutics, Inc.
Onyx Pharmaceuticals, Inc.
OphthaliX, Inc. Can-Fite BioPharma Ltd
Outlook Therapeutics, Inc.
Principia Biopharma, Inc.
Ra Pharmaceuticals Inc.
Regeneron Pharmaceuticals, Inc.
Shanghai CP Guojian Pharmaceuticals
Spirig Pharma A.G.
Theravance Biopharma, Inc.
TiGenix NV Takeda Pharmaceutical
Other Organisations Mentioned in the Report
American College of Rheumatology
National Rheumatoid Arthritis Society
US Patent Office
U.S. Food and Drug Administration (FDA)
Committee for Medicinal Products for Human Use (CHMP)
Centers for Disease Control and Prevention (CDC)
Canadian Arthritis Society
World Arthritis Day
National Rheumatoid Arthritis Society
Servizio Sanitario Nazionale (SSN)
Ministry of Health
National Institute on Aging
National Center for Biotechnology Information
Unified Health System
ANVISA (Agência Nacional de Vigilância Sanitária)
African League of Associations in Rheumatology
International League of Associations for Rheumatology
Government of Abu Dhabi
Emirates Arthritis Foundation
National Treasury of Republic of South Africa
European Medicines Agency
National Institute for Health Research (NIHR)
National Institute for Health and Care Excellence (NICE)
Institute for Quality and Efficiency in Healthcare
Institut fϋr Qualität und Wirtschaftlichkeit im Gesundheitswesen – IQWiG
To see a report overview please e-mail Sara Peerun on firstname.lastname@example.org